What is it about?
This is the largest series of patient treated with mitotane monotherapy for advanced, metastastic adrenocortical carcinoma.
Featured Image
Why is it important?
This study demonstrate that mitotane is - at least in a subset of about 20% of patients - quite effective even as monotherapy. Few patients even experience complete remission and many more long-term disease control.
Read the Original
This page is a summary of: Mitotane monotherapy in patients with advanced adrenocortical carcinoma, The Journal of Clinical Endocrinology & Metabolism, February 2018, Endocrine Society,
DOI: 10.1210/jc.2017-02591.
You can read the full text:
Contributors
The following have contributed to this page
